Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


16.04.2018

1 Am J Clin Oncol
2 Ann Thorac Surg
2 Arch Pathol Lab Med
2 BMC Cancer
2 Cancer
2 Cancer Chemother Pharmacol
2 Cancer Lett
1 Chest
1 Clin Cancer Res
5 Clin Lung Cancer
1 J Surg Oncol
1 J Thorac Cardiovasc Surg
6 J Thorac Oncol
2 Lancet Oncol
1 Mol Cancer Ther
1 N Engl J Med
3 Oncologist


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Clin Oncol

  1. TUMINELLO S, Liu B, Wolf A, Alpert N, et al
    Comparison of In-Hospital and Long-term Outcomes of Sublobar Lung Cancer Surgery by VATS and Open Techniques.
    Am J Clin Oncol. 2018 Apr 10. doi: 10.1097/COC.0000000000000440.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  2. FLORES RM, Yankelevitz DF
    Lung Cancer Screening - The True Benefit.
    Ann Thorac Surg. 2018 Apr 11. pii: S0003-4975(18)30491.
    PubMed     Text format    

  3. SANZ-SANTOS J, Serra P, Torky M, Andreo F, et al
    Systematic Compared With Targeted Staging with Endobronchial Ultrasound in Patients with Lung Cancer.
    Ann Thorac Surg. 2018 Apr 6. pii: S0003-4975(18)30434.
    PubMed     Text format     Abstract available


    Arch Pathol Lab Med

  4. SAXENA A
    Molecular Testing for Stage IV Non-Small Cell Lung Cancer Patients with Targetable Mutations Following Disease Progression.
    Arch Pathol Lab Med. 2018 Apr 12. doi: 10.5858/arpa.2018-0111.
    PubMed     Text format    

  5. PLANCHARD D, Johnson BE
    BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.
    Arch Pathol Lab Med. 2018 Apr 12. doi: 10.5858/arpa.2018-0088.
    PubMed     Text format    


    BMC Cancer

  6. HE W, Zhang H, Wang Y, Zhou Y, et al
    CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9.
    BMC Cancer. 2018;18:400.
    PubMed     Text format     Abstract available

  7. AI X, Mao F, Shen S, Shentu Y, et al
    Bexarotene inhibits the viability of non-small cell lung cancer cells via slc10a2/PPARgamma/PTEN/mTOR signaling pathway.
    BMC Cancer. 2018;18:407.
    PubMed     Text format     Abstract available


    Cancer

  8. SPIGEL DR, Burris HA 3rd, Greco FA, Shih KC, et al
    Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31290.
    PubMed     Text format     Abstract available

  9. ARBOUR KC, Riely GJ
    Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31289.
    PubMed     Text format    


    Cancer Chemother Pharmacol

  10. NIHEI S, Sato J, Harada T, Kuyama S, et al
    Antiproteinuric effects of renin-angiotensin inhibitors in lung cancer patients receiving bevacizumab.
    Cancer Chemother Pharmacol. 2018 Apr 12. pii: 10.1007/s00280-018-3580.
    PubMed     Text format     Abstract available

  11. FUKUSHIMA T, Wakatsuki Y, Kobayashi T, Sonehara K, et al
    Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2018 Apr 11. pii: 10.1007/s00280-018-3573.
    PubMed     Text format     Abstract available


    Cancer Lett

  12. RODRIGUEZ-MARTINEZ A, Torres-Duran M, Barros-Dios JM, Ruano-Ravina A, et al
    Residential radon and small cell lung cancer. A systematic review.
    Cancer Lett. 2018 Apr 11. pii: S0304-3835(18)30264.
    PubMed     Text format     Abstract available

  13. HU W, Bi ZY, Chen ZL, Liu C, et al
    Emerging landscape of circular RNAs in lung cancer.
    Cancer Lett. 2018 Apr 10. pii: S0304-3835(18)30267.
    PubMed     Text format     Abstract available


    Chest

  14. CAI J, Zhou J, Yang F, Wang J, et al
    Adoption Rate of Video-Assisted Thoracic Surgery for Lung Cancer Varies Widely in China.
    Chest. 2018;153:1073-1075.
    PubMed     Text format    


    Clin Cancer Res

  15. MCCOACH CE, Le A, Gowan K, Jones KL, et al
    Resistance mechanisms to targeted therapies in ROS1+ and ALK+ non-small cell lung cancer.
    Clin Cancer Res. 2018 Apr 10. pii: 1078-0432.CCR-17-2452.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  16. TOH CK, Ong WS, Lim WT, Tan DS, et al
    A Decade of Never-smokers Among Lung Cancer Patients-Increasing Trend and Improved Survival.
    Clin Lung Cancer. 2018 Mar 17. pii: S1525-7304(18)30055.
    PubMed     Text format     Abstract available

  17. ARDESHIR-LARIJANI F, Bhateja P, Lipka MB, Sharma N, et al
    KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2018 Mar 16. pii: S1525-7304(18)30047.
    PubMed     Text format     Abstract available

  18. GRILLEY-OLSON JE, Weiss J, Ivanova A, Villaruz LC, et al
    Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy-Naive Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2018 Mar 17. pii: S1525-7304(18)30050.
    PubMed     Text format     Abstract available

  19. REIS H, Metzenmacher M, Goetz M, Savvidou N, et al
    MET Expression in Advanced Non-Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy.
    Clin Lung Cancer. 2018 Mar 17. pii: S1525-7304(18)30052.
    PubMed     Text format     Abstract available

  20. WU YL, Sequist LV, Tan EH, Geater SL, et al
    Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
    Clin Lung Cancer. 2018 Mar 17. pii: S1525-7304(18)30051.
    PubMed     Text format     Abstract available


    J Surg Oncol

  21. FISHER SB, Rafeeq S, Hess K, Grotz TE, et al
    Elevated brain natriuretic peptide (BNP) is an early marker for patients at risk for complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS + HIPEC).
    J Surg Oncol. 2018;117:685-691.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  22. HATTORI A, Suzuki K
    New era defining a novel clinical T staging in non-small cell lung cancer.
    J Thorac Cardiovasc Surg. 2018;155:2179-2180.
    PubMed     Text format    


    J Thorac Oncol

  23. CARR SR, Akerley W, Cannon-Albright L
    Genetic Contribution to Non-Squamous, Non-Small Cell Lung Cancer in Non-Smokers.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30263.
    PubMed     Text format     Abstract available

  24. MA Y, Zheng X, Zhao H, Fang W, et al
    First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30264.
    PubMed     Text format     Abstract available

  25. SANDBERG Y, den Bakker MA
    Small cell lung cancer presenting as carcinocythemia.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30269.
    PubMed     Text format    

  26. OSTIOS-GARCIA L, Faig J, Leonardi GC, Adeni AE, et al
    Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30270.
    PubMed     Text format     Abstract available

  27. OWADA-OZAKI Y, Muto S, Takagi H, Inoue T, et al
    Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30509.
    PubMed     Text format     Abstract available

  28. DONINGTON JS, Kim YT, Tong B, Moreira AL, et al
    Progress in the management of Early Stage Non-Small Cell Lung Cancer in 2017.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30508.
    PubMed     Text format     Abstract available


    Lancet Oncol

  29. WRANGLE JM, Velcheti V, Patel MR, Garrett-Mayer E, et al
    ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30148.
    PubMed     Text format     Abstract available

  30. ROLFO C, Smits ELJ
    Combining top-ranked immunotherapeutics in lung cancer.
    Lancet Oncol. 2018 Apr 5. pii: S1470-2045(18)30186.
    PubMed     Text format    


    Mol Cancer Ther

  31. BOCKORNY B, Rusan M, Chen W, Liao RG, et al
    RAS-MAPK reactivation facilitates acquired resistance in FGFR1-amplified lung cancer and underlies a rationale for upfront FGFR-MEK blockade.
    Mol Cancer Ther. 2018 Apr 13. pii: 1535-7163.MCT-17-0464.
    PubMed     Text format     Abstract available


    N Engl J Med

  32. MAMDANI H, Grethlein SJ
    Pulmonary Metastases from Chondroblastic Osteosarcoma.
    N Engl J Med. 2018;378:1429.
    PubMed     Text format    


    Oncologist

  33. LABABEDE O, Meziane MA
    The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0659.
    PubMed     Text format     Abstract available

  34. CHU CY, Choi J, Eaby-Sandy B, Langer CJ, et al
    Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0582.
    PubMed     Text format     Abstract available

  35. AHLUWALIA MS, Becker K, Levy BP
    Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer.
    Oncologist. 2018 Apr 12. pii: theoncologist.2017-0572.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: